Abstract
This systematic review and meta-analysis of cardiovascular outcome trials examines the effects of GLP-1RA in the treatment of patients with type 2 diabetes.
Citation
Kristensen SL, Rørth R, Jhund PS, et al. Lancet Diabetes Endocrinol 2019;7:776–85.
